Telo Genomics Stock Price, News & Analysis

Welcome to our dedicated page for Telo Genomics news (Ticker: TDSGF), a resource for investors and traders seeking the latest updates and insights on Telo Genomics stock.

Telo Genomics Corp (OTCQB: TDSGF; TSXV: TELO) regularly publishes news related to its telomere-based diagnostic and prognostic technologies, with a strong emphasis on multiple myeloma and minimal residual disease (MRD) testing. Company updates often describe progress in clinical validation, scientific presentations, and collaborations that support its liquid biopsy and telomere analytics platform.

Recent announcements highlight Telo Genomics’ MRD work in multiple myeloma, including a retrospective blood-based MRD study with the University of Athens and prospective MRD trials with institutions such as Cleveland Clinic and Jewish General Hospital. News items also cover poster presentations and abstract acceptances at major hematology and myeloma meetings, including the American Society of Hematology Annual Meeting and the International Myeloma Society Annual Meeting, where the company showcases its TeloView®-based MRD methodologies.

Investors and observers can find coverage of Telo Genomics’ developments in blood-based MRD workflows, single-cell risk profiling of MRD and circulating tumor cells, and the use of 3D telomere profiling to assess relapse risk and disease progression. Additional news may include operational updates, such as the relocation and expansion of clinical laboratories in the Greater Toronto Area, investor relations agreements, and corporate communications relating to commercialization efforts.

This news page is useful for tracking how Telo Genomics advances its telomere platform, expands its clinical evidence base, and participates in key industry conferences and summits focused on multiple myeloma and precision oncology. Readers interested in TDSGF can use the news feed to follow scientific milestones, clinical collaborations, and corporate disclosures over time.